{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T09:07:29Z","timestamp":1716973649258},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,18]]},"DOI":"10.7759\/cureus.47264","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T14:12:52Z","timestamp":1697638372000},"source":"Crossref","is-referenced-by-count":1,"title":["Characteristics of Top-Searched Individuals in Japan\u2019s Yen for Docs Conflicts of Interest Database During the COVID-19 Pandemic"],"prefix":"10.7759","author":[{"given":"Yudai","family":"Kaneda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanao","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihajlo","family":"Jakovljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016408","article-title":"Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review","volume":"7","author":"Fickweiler F","year":"2017","unstructured":"Fickweiler F, Fickweiler W, Urbach E. Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review. BMJ Open. 2017, 7:e016408. 10.1136\/bmjopen-2017-016408","journal-title":"BMJ Open"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-023-00448-6","article-title":"Could high continuity of care (COC) have a negative impact on subjective health of hypertensive patients? A Japanese perspective","volume":"21","author":"Kumagai N","year":"2023","unstructured":"Kumagai N, Nishimura S, Jakovljevi\u0107 M. Could high continuity of care (COC) have a negative impact on subjective health of hypertensive patients? A Japanese perspective. Cost Eff Resour Alloc. 2023, 21:39. 10.1186\/s12962-023-00448-6","journal-title":"Cost Eff Resour Alloc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4234","article-title":"Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review","volume":"371","author":"Nejstgaard CH","year":"2020","unstructured":"Nejstgaard CH, Bero L, Hr\u00f3bjartsson A, J\u00f8rgensen AW, J\u00f8rgensen KJ, Le M, Lundh A. Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review. BMJ. 2020, 371:m4234. 10.1136\/bmj.m4234","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/009885881003600103","article-title":"Confronting conflict: addressing institutional conflicts of interest in academic medical centers","volume":"36","author":"Liang BA","year":"2010","unstructured":"Liang BA, Mackey T. Confronting conflict: addressing institutional conflicts of interest in academic medical centers. Am J Law Med. 2010, 36:136-87. 10.1177\/009885881003600103","journal-title":"Am J Law Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hpm.3618","article-title":"Japan's valsartan clinical trials shambles; time for fundamental changes","volume":"38","author":"Ozaki A","year":"2023","unstructured":"Ozaki A, Harada K, Murayama A, et al.. Japan's valsartan clinical trials shambles; time for fundamental changes. Int J Health Plann Manage. 2023, 38:557-68. 10.1002\/hpm.3618","journal-title":"Int J Health Plann Manage"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.762637","article-title":"How do institutional conflicts of interest between pharmaceutical companies and the healthcare sector become corrupt? A case study of scholarship donations between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan","volume":"9","author":"Ozaki A","year":"2021","unstructured":"Ozaki A, Murayama A, Harada K, Saito H, Sawano T, Tanimoto T, Ozieranski P. How do institutional conflicts of interest between pharmaceutical companies and the healthcare sector become corrupt? A case study of scholarship donations between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan. Front Public Health. 2021, 9:762637. 10.3389\/fpubh.2021.762637","journal-title":"Front Public Health"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i3692","article-title":"Margaret McCartney: optional disclosure of payments is pointless","volume":"354","author":"McCartney M","year":"2016","unstructured":"McCartney M. Margaret McCartney: optional disclosure of payments is pointless. BMJ. 2016, 354:i3692. 10.1136\/bmj.i3692","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1305090","article-title":"Sunlight as disinfectant--new rules on disclosure of industry payments to physicians","volume":"368","author":"Rosenthal MB","year":"2013","unstructured":"Rosenthal MB, Mello MM. Sunlight as disinfectant--new rules on disclosure of industry payments to physicians. N Engl J Med. 2013, 368:2052-4. 10.1056\/NEJMp1305090","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-017-4012-3","article-title":"Public awareness of and contact with physicians who receive industry payments: a national survey","volume":"32","author":"Pham-Kanter G","year":"2017","unstructured":"Pham-Kanter G, Mello MM, Lehmann LS, Campbell EG, Carpenter D. Public awareness of and contact with physicians who receive industry payments: a national survey. J Gen Intern Med. 2017, 32:767-74. 10.1007\/s11606-017-4012-3","journal-title":"J Gen Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.1947","article-title":"US nationwide disclosure of industry payments and public trust in physicians","volume":"2","author":"Kanter GP","year":"2019","unstructured":"Kanter GP, Carpenter D, Lehmann LS, Mello MM. US nationwide disclosure of industry payments and public trust in physicians. JAMA Netw Open. 2019, 2:e191947. 10.1001\/jamanetworkopen.2019.1947","journal-title":"JAMA Netw Open"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024020","article-title":"Effect of the public disclosure of industry payments information on patients: results from a population-based natural experiment","volume":"9","author":"Kanter GP","year":"2019","unstructured":"Kanter GP, Carpenter D, Lehmann L, Mello MM. Effect of the public disclosure of industry payments information on patients: results from a population-based natural experiment. BMJ Open. 2019, 9:e024020. 10.1136\/bmjopen-2018-024020","journal-title":"BMJ Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001754","article-title":"Act II of the Sunshine Act","volume":"11","author":"Pham-Kanter G","year":"2014","unstructured":"Pham-Kanter G. Act II of the Sunshine Act. PLoS Med. 2014, 11:e1001754. 10.1371\/journal.pmed.1001754","journal-title":"PLoS Med"},{"key":"ref13","unstructured":"Open payments. (2023). Accessed. August 10, 2023: https:\/\/openpaymentsdata.cms.gov\/."},{"key":"ref14","unstructured":"Disclosure UK. (2023). Accessed. August 10, 2023: https:\/\/www.abpi.org.uk\/reputation\/disclosure-uk\/."},{"key":"ref15","unstructured":"Dollars for Docs. (2023). Accessed. August 26, 2023: https:\/\/projects.propublica.org\/docdollars\/."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2020.03.011","article-title":"Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: analysis of payment data in 2016","volume":"124","author":"Ozaki A","year":"2020","unstructured":"Ozaki A, Saito H, Senoo Y, et al.. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: analysis of payment data in 2016. Health Policy. 2020, 124:727-35. 10.1016\/j.healthpol.2020.03.011","journal-title":"Health Policy"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.15171\/ijhpm.2018.20","article-title":"Sunshine policies and murky shadows in Europe: disclosure of pharmaceutical industry payments to health professionals in nine European countries","volume":"7","author":"Fabbri A","year":"2018","unstructured":"Fabbri A, Santos A, Mezinska S, Mulinari S, Mintzes B. Sunshine policies and murky shadows in Europe: disclosure of pharmaceutical industry payments to health professionals in nine European countries. Int J Health Policy Manag. 2018, 7:504-9. 10.15171\/ijhpm.2018.20","journal-title":"Int J Health Policy Manag"},{"key":"ref18","unstructured":"Japan - country commercial guide. (2022). Accessed. August 26, 2023: https:\/\/www.trade.gov\/country-commercial-guides\/japan-pharmaceuticals."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12992-022-00902-9","article-title":"International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency","volume":"19","author":"Ozieranski P","year":"2023","unstructured":"Ozieranski P, Saito H, Rickard E, Mulinari S, Ozaki A. International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency. Global Health. 2023, 19:14. 10.1186\/s12992-022-00902-9","journal-title":"Global Health"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S266386","article-title":"Predictors of (in)efficiencies of healthcare expenditure among the leading Asian economies - comparison of OECD and non-OECD nations","volume":"13","author":"Jakovljevic M","year":"2020","unstructured":"Jakovljevic M, Sugahara T, Timofeyev Y, Rancic N. Predictors of (in)efficiencies of healthcare expenditure among the leading Asian economies - comparison of OECD and non-OECD nations. Risk Manag Healthc Policy. 2020, 13:2261-80. 10.2147\/RMHP.S266386","journal-title":"Risk Manag Healthc Policy"},{"key":"ref21","unstructured":"Yen for Docs [in Japanese]. Accessed. August 22, 2023: https:\/\/yenfordocs.jp\/."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024928","article-title":"Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study","volume":"9","author":"Parker L","year":"2019","unstructured":"Parker L, Karanges EA, Bero L. Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study. BMJ Open. 2019, 9:e024928. 10.1136\/bmjopen-2018-024928","journal-title":"BMJ Open"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01258-7","article-title":"Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990-2050","volume":"398","year":"2021","unstructured":"Tracking development assistance for health and for COVID-19. a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990-2050. Lancet. 2021, 398:1317-43. 10.1016\/S0140-6736(21)01258-7","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.12.002","article-title":"Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies","volume":"27","author":"Murayama A","year":"2020","unstructured":"Murayama A, Ozaki A, Saito H, Sawano T, Sah R, Tanimoto T. Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies. Clin Microbiol Infect. 2020, 27:805-7. 10.1016\/j.cmi.2020.12.002","journal-title":"Clin Microbiol Infect"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.21037\/jphe-23-42","article-title":"Public health and personal freedom: the question of mask-wearing","author":"Kaneda Y","year":"2023","unstructured":"Kaneda Y. Public health and personal freedom: the question of mask-wearing. J Public Health Emerg. 2023, 10.21037\/jphe-23-42","journal-title":"J Public Health Emerg"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2023-0037","article-title":"Potential risk of overlooking biased reporting of vaccination against novel coronavirus disease 2019: lessons from Japan\u2019s experience with the human papillomavirus vaccine","volume":"6","author":"Kaneda Y","year":"2023","unstructured":"Kaneda Y, Namba M. Potential risk of overlooking biased reporting of vaccination against novel coronavirus disease 2019: lessons from Japan\u2019s experience with the human papillomavirus vaccine. JMA Journal. 2023, 6:513-4. 10.31662\/jmaj.2023-0037","journal-title":"JMA Journal"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1265\/ehpm.22-00266","article-title":"The influence of information sources on intention changes to receive COVID-19 vaccination: a prospective cohort study in Japan","volume":"28","author":"Hori D","year":"2023","unstructured":"Hori D, Takahashi T, Kaneda Y, Ozaki A, Tabuchi T. The influence of information sources on intention changes to receive COVID-19 vaccination: a prospective cohort study in Japan. Environ Health Prev Med. 2023, 28:10. 10.1265\/ehpm.22-00266","journal-title":"Environ Health Prev Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/08989621.2013.788383","article-title":"Taking financial relationships into account when assessing research","volume":"20","author":"Resnik DB","year":"2013","unstructured":"Resnik DB, Elliott KC. Taking financial relationships into account when assessing research. Account Res. 2013, 20:184-205. 10.1080\/08989621.2013.788383","journal-title":"Account Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph191710933","article-title":"The influence of SNS on policy support to mitigate public health crises: the mediating role of general and personal risk perceptions","volume":"19","author":"Kim S","year":"2022","unstructured":"Kim S. The influence of SNS on policy support to mitigate public health crises: the mediating role of general and personal risk perceptions. Int J Environ Res Public Health. 2022, 19:10933. 10.3390\/ijerph191710933","journal-title":"Int J Environ Res Public Health"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2014.881254","article-title":"Contemporary generic market in Japan - key conditions to successful evolution","volume":"14","author":"Jakovljevic MB","year":"2014","unstructured":"Jakovljevic MB, Nakazono S, Ogura S. Contemporary generic market in Japan - key conditions to successful evolution. Expert Rev Pharmacoecon Outcomes Res. 2014, 14:181-94. 10.1586\/14737167.2014.881254","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref31","article-title":"Report of online conference on measures against coronavirus in Japan organized by president of subcommittee on novel coronavirus disease control and medical students","volume":"38","author":"Kaneda Y","year":"2023","unstructured":"Kaneda Y, Itaya Y, Yamada K, Sekine K, Kido H. Report of online conference on measures against coronavirus in Japan organized by president of subcommittee on novel coronavirus disease control and medical students. Int Health. 2023, 38:25-27.","journal-title":"Int Health"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30905","article-title":"Guillain-Barre syndrome after COVID-19 vaccination: a secondary analysis of domestic safety data by the Japanese government","volume":"14","author":"Kaneda Y","year":"2022","unstructured":"Kaneda Y, Hashimoto T, Kaneda U, et al.. Guillain-Barre syndrome after COVID-19 vaccination: a secondary analysis of domestic safety data by the Japanese government. Cureus. 2022, 14:e30905. 10.7759\/cureus.30905","journal-title":"Cureus"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.21037\/aes-22-45","article-title":"Optic neuritis after mRNA vaccination against COVID-19: a secondary analysis of post-approval national safety data by the Japanese government","volume":"8","author":"Kaneda Y","year":"2023","unstructured":"Kaneda Y, Kawasaki C, Namba M, Kaneda U, Ozaki A, Tanimoto T. Optic neuritis after mRNA vaccination against COVID-19: a secondary analysis of post-approval national safety data by the Japanese government. Ann Eye Sci. 2023, 8:3. 10.21037\/aes-22-45","journal-title":"Ann Eye Sci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1277746","article-title":"Japan's COVID-19 response: underutilized beds and misused funds","volume":"11","author":"Saito Y","year":"2023","unstructured":"Saito Y, Ozaki A, Tanimoto T, Takita M, Kami M. Japan's COVID-19 response: underutilized beds and misused funds. Front Public Health. 2023, 11:1277746. 10.3389\/fpubh.2023.1277746","journal-title":"Front Public Health"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059886","article-title":"Association between COVID-19 incidence and postponement or cancellation of elective surgeries in Japan until September 2020: a cross-sectional, web-based survey","volume":"12","author":"Kurokawa T","year":"2022","unstructured":"Kurokawa T, Ozaki A, Bhandari D, et al.. Association between COVID-19 incidence and postponement or cancellation of elective surgeries in Japan until September 2020: a cross-sectional, web-based survey. BMJ Open. 2022, 12:e059886. 10.1136\/bmjopen-2021-059886","journal-title":"BMJ Open"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-022-00337-4","article-title":"Predictors of loss due to pharmaceutical fraud: evidence from the U.S","volume":"20","author":"Timofeyev Y","year":"2022","unstructured":"Timofeyev Y, Hayes SA, Jakovljevic MB. Predictors of loss due to pharmaceutical fraud: evidence from the U.S. Cost Eff Resour Alloc. 2022, 20:6. 10.1186\/s12962-022-00337-4","journal-title":"Cost Eff Resour Alloc"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025029","article-title":"Effect of different financial competing interest statements on readers' perceptions of clinical educational articles: a randomised controlled trial","volume":"9","author":"Schroter S","year":"2019","unstructured":"Schroter S, Pakpoor J, Morris J, Chew M, Godlee F. Effect of different financial competing interest statements on readers' perceptions of clinical educational articles: a randomised controlled trial. BMJ Open. 2019, 9:e025029. 10.1136\/bmjopen-2018-025029","journal-title":"BMJ Open"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s12178-015-9270-2","article-title":"Conflicts of interest in research: looking out for number one means keeping the primary interest front and center","volume":"8","author":"Romain PL","year":"2015","unstructured":"Romain PL. Conflicts of interest in research: looking out for number one means keeping the primary interest front and center. Curr Rev Musculoskelet Med. 2015, 8:122-7. 10.1007\/s12178-015-9270-2","journal-title":"Curr Rev Musculoskelet Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39270","article-title":"Rethinking Japan\u2019s infallibility principle for a better pandemic response","volume":"15","author":"Kaneda Y","year":"2023","unstructured":"Kaneda Y, Ozaki A, Tanimoto T. Rethinking Japan\u2019s infallibility principle for a better pandemic response. Cureus. 2023, 15:e39270. 10.7759\/cureus.39270","journal-title":"Cureus"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1468","article-title":"Revisiting Japan's early COVID-19 countermeasures","volume":"6","author":"Kaneda Y","year":"2023","unstructured":"Kaneda Y, Higuchi Y, Takahashi K. Revisiting Japan's early COVID-19 countermeasures. Health Sci Rep. 2023, 6:e1468. 10.1002\/hsr2.1468","journal-title":"Health Sci Rep"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13628","article-title":"Japan's COVID-19 treatment strategy: an examination of approved oral medications","author":"Higuchi Y","year":"2023","unstructured":"Higuchi Y, Kaneda Y, Tanimoto T. Japan's COVID-19 treatment strategy: an examination of approved oral medications. Clin Transl Sci. 2023, 10.1111\/cts.13628","journal-title":"Clin Transl Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/196855-characteristics-of-top-searched-individuals-in-japans-yen-for-docs-conflicts-of-interest-database-during-the-covid-19-pandemic","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:10Z","timestamp":1707509470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/196855-characteristics-of-top-searched-individuals-in-japans-yen-for-docs-conflicts-of-interest-database-during-the-covid-19-pandemic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.47264","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,18]]}}}